The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Kaken Banking on Clenafin to Boost Dermatology Biz
November 27, 2014
- Bulk Antibody Production Efficiency Up 10-fold, Production Costs Down “Several-fold” Since 2002: Chugai
November 26, 2014
- Amgen Calls Off Clinical Studies of Rilotumumab for Gastric Cancer
November 26, 2014
- MSD to Ensure Appropriate Use of Insomnia Drug Belsomra
November 26, 2014
- Eisai Launches Halaven in Brazil
November 26, 2014
- Eisai Launches Fycompa in Hong Kong
November 26, 2014
- MSD Seeks Japan Regulatory Approval for Once-Weekly DPP-4 Inhibitor
November 25, 2014
- Rushed Settlements Dragged Down Drug Delivery Prices: Vital KSK Exec
November 25, 2014
- Merck Serono Transfers Marketing Rights for Saizen to Fujifilm Pharma
November 25, 2014
- Top Two Japan Universities to Offer Undergrads Amgen-Sponsored Lab Experience Programs
November 21, 2014
- Domestic Subgroup Analysis Confirms Efficacy of Cimzia: Astellas, UCB Japan
November 21, 2014
- Kissei Files NDA for Hyperphosphatemia Treatment in Japan
November 21, 2014
- CareNet Teams Up with Indian Firm on Marketing Solutions for Drug Makers
November 20, 2014
- Ranbaxy Sues FDA for Revoking Tentative Approvals for Nexium, Valcyte Generics
November 20, 2014
- Takeda Ordered to Pay US$155,000 for Spoliation of Evidence in Actos Case
November 20, 2014
- Nipro Pharma Joins Hands with Thai Firm on Drug Distribution
November 20, 2014
- Mirena Approved for Dysmenorrhea Based on Data from Public Domain: Bayer Yakuhin
November 20, 2014
- 30% of Pharmacies Handling Blopress AGs Likely to Use Other Makers’ Generics: Survey
November 19, 2014
- Topical Combination Agent for Plaque Psoriasis Showed Superiority to Monotherapies in PIII Trial: Maruho
November 19, 2014
- Giotrif Extends Overall Survival in Japanese NSCLC Patients with Del19 EGFR Mutation: NBI
November 19, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…